How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    a. Has all of the relevant evidence been taken into account?

  • Question on Consultation

    b. Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    c. Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    d. Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Draft guidance consultation

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about setmelanotide

Marketing authorisation indication

2.1

Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is indicated for 'the treatment of obesity and the control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 2 years of age and above'.

Dosage in the marketing authorisation

Price

2.3

The list price of setmelanotide is £2,376.00 for a 10 mg/ml vial for injection (excluding VAT; BNF online, accessed June 2026).

2.4

The company has a commercial arrangement (simple discount patient access scheme). This makes setmelanotide available to the NHS with a discount. The size of the discount is commercial in confidence.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Rhythm Pharmaceuticals will be included here when guidance is published.